Edition:
United Kingdom

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

199.70SEK
5:00pm BST
Change (% chg)

-3.50kr (-1.72%)
Prev Close
203.20kr
Open
202.80kr
Day's High
204.60kr
Day's Low
199.50kr
Volume
65,755
Avg. Vol
140,654
52-wk High
290.00kr
52-wk Low
158.00kr

Latest Key Developments (Source: Significant Developments)

Hansa Medical Q1 Operating Loss Widens To SEK 46.6 Million
Wednesday, 25 Apr 2018 

April 25 (Reuters) - HANSA MEDICAL AB ::Q1 OPERATING LOSS SEK 46.6 MILLION VERSUS LOSS SEK 44.8 MILLION YEAR AGO.Q1 NET SALES SEK 588,000 VERSUS SEK 1.1 MILLION YEAR AGO.  Full Article

‍Hansa Medical Contemplates Directed Share Issue To Raise About Sek 545 mln​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Hansa Medical Ab ::‍HANSA MEDICAL CONTEMPLATES A DIRECTED SHARE ISSUE TO RAISE APPROXIMATELY SEK 545 MILLION​.HANSA MEDICAL -COMMISSIONED EVERCORE, RBC CAPITAL AND SEB, TO INVESTIGATE POSSIBILITY OF UNDERTAKING NEW ISSUE OF SHARES TO INSTITUTIONAL INVESTORS.‍INTENDS TO USE PROCEEDS FROM DIRECTED ISSUE TO FUND CONTINUED DEVELOPMENT OF COMPANY'S EXISTING PORTFOLIO​.  Full Article

Hansa Medical Q3 operating loss up at SEK ‍​37.4 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - HANSA MEDICAL AB ::Q3 OPERATING LOSS SEK ‍​37.4 MILLION VERSUS LOSS SEK 27.0 MILLION YEAR AGO.Q3 NET REVENUE SEK ‍​678,000 VERSUS SEK 0.9 MILLION YEAR AGO.  Full Article

Hansa Medical: sudden death of CEO Göran Arvidson​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - HANSA MEDICAL AB :‍ANNOUNCES SUDDEN DEATH OF CEO GÖRAN ARVIDSON​.‍CHAIRMAN ULF WIINBERG WILL SERVE AS ACTING CEO.‍BIRGIT STATTIN NORINDER WILL TAKE OVER ROLE AS CHAIRMAN OF BOARD UNTIL FURTHER NOTICE​.  Full Article

Hansa Medical: preclinical results confirm IdeS potential in cancer immunotherapy
Tuesday, 23 May 2017 

May 23 (Reuters) - HANSA MEDICAL AB :PUBLISHED PRECLINICAL RESULTS CONFIRM IDES POTENTIAL IN CANCER IMMUNOTHERAPY.PUBLISHED PRECLINICAL RESULTS CONFIRM IDES POTENTIAL IN CANCER IMMUNOTHERAPY.PUBLISHED FINDINGS DEMONSTRATE HOW PRE-TREATMENT WITH IDES IN TUMOUR ANIMAL MODELS CAN INCREASE EFFICACY OF CURRENTLY AVAILABLE ANTIBODY BASED CANCER THERAPIES.  Full Article

Hansa Medical Q2 operating loss widens to SEK 30.7 million
Thursday, 21 Jul 2016 

Hansa Medical AB : Q2 net sales 0.5 million Swedish crowns ($58,245) versus 0.5 million crowns year ago .Q2 operating loss 30.7 million crowns versus loss 22.5 million crowns year ago.  Full Article

Hansa Medical acquires UK-based Immago Biosystems Ltd
Tuesday, 19 Jul 2016 

Hansa Medical AB : Acquires United Kingdom based Immago Biosystems Ltd . Acquisition will not have a significant impact on Hansa Medical result for 2016 . Sum of acquisition was not disclosed .Immago Biosystems Ltd is a University of Oxford-spinout focused on the enhancement of antibody based cancer therapies using antibody-modulating enzymes.  Full Article

BRIEF-Hansa Medical Q1 Operating Loss Widens To SEK 46.6 Million

* Q1 OPERATING LOSS SEK 46.6 MILLION VERSUS LOSS SEK 44.8 MILLION YEAR AGO